- Home
- ROOT vs HELP Comparison
ROOT vs HELP Comparison
Compare ROOT & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROOT | HELP |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 889.5M | 889.9M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ROOT | HELP |
|---|---|---|
| Price | $53.87 | $12.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $92.40 | $51.50 |
| AVG Volume (30 Days) | 189.5K | ★ 1.6M |
| Earning Date | 05-06-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.96 | N/A |
| EPS | ★ 3.58 | N/A |
| Revenue | ★ $1,517,100,000.00 | N/A |
| Revenue This Year | $11.73 | N/A |
| Revenue Next Year | $12.80 | N/A |
| P/E Ratio | $14.55 | ★ N/A |
| Revenue Growth | ★ 28.95 | N/A |
| 52 Week Low | $40.91 | $3.76 |
| 52 Week High | $104.47 | $14.35 |
Technical Indicators
Market Signals| Indicator | ROOT | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 45.03 | 60.38 |
| Support Level | $51.00 | $4.41 |
| Resistance Level | $58.93 | $14.35 |
| Average True Range (ATR) | 2.31 | 0.94 |
| MACD | -0.19 | -0.14 |
| Stochastic Oscillator | 25.35 | 53.47 |
Price Performance
Historical ComparisonAbout ROOT Root Inc.
Root Inc develops and launches a direct-to-consumer personal automobile insurance and mobile technology company. It generates revenue from the sales of auto insurance policies within the United States.
About HELP Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.